Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–2024—doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Daniel Schröder und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections,…. Hauptthemen laut MEDLINE: Neisseria gonorrhoeae, Gonorrhea, Tetracycline Resistance, Anti-Bacterial Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: World Health Organization, Örebro County Council Research Committee, Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden.
Abstract (Originalsprache)
Objectives
Doxycycline post-exposure prophylaxis (doxycycline-PEP) can reduce incident cases of syphilis, chlamydia and possibly gonorrhoea especially among men who have sex with men with recent bacterial sexually transmitted infections (STIs). Owing to potential implementation of doxycycline-PEP internationally, global tetracycline/doxycycline resistance data for contemporary Neisseria gonorrhoeae isolates has become imperative. We report tetracycline resistance data for gonococcal isolates (n = 2993) from eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) countries in three WHO regions in 2021–2024, i.e. to estimate potential impact of doxycycline-PEP on the incident gonorrhoea cases in these WHO EGASP countries.
Methods
WHO EGASP isolates cultured from men with urethral discharge in Cambodia (n = 482), Indonesia (n = 101), Malawi (n = 121), The Philippines (n = 843), South Africa (n = 597), Thailand (n = 250), Uganda (n = 350) and Vietnam (n = 249) in 2021–2024 were examined. MICs (mg/L) of tetracycline were determined using Etest.
Results
The tetracycline resistance (range) using the current EUCAST (MIC > 0.5 mg/L) and CLSI (MIC > 1 mg/L) clinical resistance breakpoints in the eight WHO EGASP countries was 92.2% (83.5%–99.6%) and 80.6% (66.3%–98.6%), respectively. Using a previous minocycline-PEP resistance breakpoint (MIC > 2 mg/L) and breakpoint for high-level plasmid (tetM)-mediated tetracycline resistance (MIC > 8 mg/L), the tetracycline resistance (range) was 77.3% (47.4%–98.6%) and 74.3% (31.3%–98.6%), respectively.
Conclusions
The exceedingly high levels of gonococcal tetracycline resistance (independent of resistance breakpoint used) in the eight WHO EGASP countries elucidate that doxycycline-PEP will unlikely significantly reduce the gonorrhoea cases in these countries. Furthermore, doxycycline-PEP might rapidly select for additional gonococcal strains with tetracycline resistance (low- and high-level) and MDR/XDR strains, i.e. because these strains are mostly resistant to tetracycline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, National Reference Laboratory for Sexually Transmitted Infections, Ör…
- Division of AIDS and STIs, Department of Disease Control and Prevention, Bangrak STIs Center, Thailand Ministry of Public Health, Bangkok, Thailand.
- National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
- National Center for HIV/AIDS, Dermatology and Sexually Transmitted Diseases, Phnom Penh, Cambodia.
- UNC Project Malawi, Lilongwe, Malawi.
- Research Institute for Tropical Medicine, Department of Health, Manila, The Philippines.
ORCID-Profile: Rossaphorn Kittiyaowamarn, Etienne Müller, Ismael Maatouk, Magnus Unemo
Förderung
- World Health Organization
- Örebro County Council Research Committee
- Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden
Zitieren
APA
Schröder, D., Cherdtrakulkiat, T., Doanh, L. H., Golparian, D., Heng, L. S., Hoffman, I., Jacobsson, S., Jamoralin, M. C., Kakooza, F., Kittiyaowamarn, R., Kyambadde, P., Maseko, V., Matoga, M., Müller, E., Nguyen, T. T. P., Ouk, V., Setiawaty, V., Sia, S. B., Sulaiman, V., …, & WHO EGASP tetracycline study group (2025). Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–2024—doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf066
Vancouver
Schröder D, Cherdtrakulkiat T, Doanh LH, Golparian D, Heng LS, Hoffman I, et al. Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–2024—doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf066
BibTeX
@article{Schrder2025,
author = {Schröder, Daniel and Cherdtrakulkiat, Thitima and Doanh, Le Huu and Golparian, Daniel and Heng, Lon Say and Hoffman, Irving and Jacobsson, Susanne and Jamoralin, Manuel C and Kakooza, Francis and Kittiyaowamarn, Rossaphorn and Kyambadde, Peter and Maseko, Venessa and Matoga, Mitch and Müller, Etienne and Nguyen, Thuy Thi Phan and Ouk, Vichea and Setiawaty, Vivi and Sia, Sonia B and Sulaiman, Verawati and Virak, Mot and Thuy Van, Nguyen Thi and Wi, Teodora and Maatouk, Ismael and Unemo, Magnus and WHO EGASP tetracycline study group, WHO EGASP tetracycline study group},
title = {Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–2024—doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf066}
}
EUVIMED